Liposomes modified by carbohydrate ligands can target B cells for the treatment of B-cell lymphomas

[Guest guest]

Blank Liposomes modified by carbohydrate ligands can target B cells for the

treatment of B-cell lymphomas.

GJ Boons

Expert Rev Vaccines, November 1, 2010; 9(11): 1251-6.

Complex Carbohydrate Research Center, University of Georgia, 315 Riverbend Road,

Athens, GA 30602, USA. gjboons@... .

Evaluation of: Chen WC, Completo GC, Sigal DS, Crocker PR, Saven A, son JC.

In vivo targeting of B-cell lymphoma with glycan ligands of CD22. Blood 115(23),

4778-4786 (2010). A strategy has been developed to deliver selectively

chemotherapeutic drugs to B cells by employing doxorubicin-loaded liposomes

modified by a ligand for the B-cell-specific cell-surface protein CD22, also

known as Siglec-2. The liposomes bound in a rapid and saturable manner to the

human Burkitt lymphoma Daudi B-cell line and exhibited significantly higher

cytotoxicity in vitro and in vivo compared with similar untargeted liposomes.

The CD22-targeted liposome bound to B cells isolated from lymphoma patients and

although binding was proportional to CD22 expression on the cell surface, low

levels of expression on chronic lymphocytic leukemia cells were sufficient to

effect cell neutralization. The glycan-based strategy for delivery of

chemotherapeutic agents may provide a new strategy for the treatment of B-cell

lymphomas.

PMID: 21087105